Testing lipoprotein levels in patients with lymphedema
Testing for Increased Lipoproteins (a) [LP(a)] in Lymphedema Patients: Li-LY
This study is testing if people with lymphedema have higher levels of a certain type of fat in their blood that could increase their risk of heart problems.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Sponsor | Centre Hospitalier Universitaire de Nice Academic / other |
| Locations | 2 sites (Nice, France and 1 other locations) |
| Trial ID | NCT05962827 on ClinicalTrials.gov |
What this trial studies
This study investigates the levels of lipoprotein(a) in patients suffering from lymphedema, a condition characterized by lymph accumulation in tissues. Participants undergoing intensive inpatient decongestive therapy will have their blood tested for various lipid levels, including lipoprotein(a), to assess cardiovascular risk. The research aims to understand the relationship between lymphedema and elevated lipoprotein(a) levels, which are linked to increased cardiovascular risks. The study is conducted at Nice University Hospital, focusing on both primary and secondary lymphedema patients.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 with confirmed primary or secondary lymphedema.
Not a fit: Patients who are pregnant, breastfeeding, or undergoing secondary cardiovascular prevention may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved cardiovascular risk management in lymphedema patients.
How similar studies have performed: While the specific approach of testing lipoprotein(a) in lymphedema patients is novel, similar studies have shown the importance of lipid management in cardiovascular risk.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients over 18 years of age. * Patient with primary or secondary lymphedema confirmed at consultation or in day hospital. * Signature of informed consent. * Person affiliated to or benefiting from a social security scheme Exclusion Criteria: * Person refusing informed consent. * Pregnant or breast-feeding women (urine pregnancy test performed in women of -childbearing age). * Patients undergoing secondary cardiovascular prevention (MI, stroke, AOMI, etc.). * Persons deprived of their liberty by judicial or administrative decision, persons under legal protection.
Where this trial is running
Nice, France and 1 other locations
- Chu de Nice — Nice, France, France (Recruiting)
- Centre antoine lacassagne — Nice, France, France (Terminated)
Study contacts
- Principal investigator: Verena FASSBENDER — Centre Hospitalier Universitaire de Nice
- Study coordinator: Verena FASSBENDER
- Email: fassbender.v@chu-nice.fr
- Phone: 0492034702
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.